Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$27,000.00
The Immunotherapeutic Targeting of Glioblastoma at the Minimal Residual Disease State.
FY 2024-25
Summary
Glioblastoma (GBM) is the most common and deadliest type of primary brain tumor in adults, with a staggering 90-95% of patients losing their lives to the disease within 5 years of diagnosis. This is because glioblastoma recurs in almost all patient despite an aggressive standard of care (SoC) treatment involving surgery followed by radiotherapy and chemotherapy. There currently exists no standardized treatment protocol upon recurrence. To better understand GBM recurrence, we have previously adapted the clinical SoC treatment to mice engrafted with GBM to model GBM at its lowest point post-treatment. This stage of cancer progression is called the minimal residual disease (MRD). Given that the GBM is practically impossible to treat upon recurrence, MRD presents a valuable yet underutilized window of opportunity for pre-emptive intervention. Upon analyzing cellular expression data extracted from this model, I identified protein tyrosine phosphatase receptor type Z1 (PTPRZ1) as one of the highest expressed genes at MRD. While PTPRZ1 has previously been shown to promote tumor growth in GBM pre-treatment, its role in driving tumor recurrence is yet to be characterized. I hypothesize that interfering with PTPRZ1 activity will decrease the protumor characteristics of recurrent GBM. Furthermore, using engineered T cells to target PTPRZ1 and attack surviving cancer cells post-treatment may significantly prolong remission. GBM recurrence is almost inevitable and ultimately fatal. Treatment at MRD may delay recurrence by targeting GBM when it is vulnerable, thereby significantly improving patient outcomes and quality of life.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529644
Name
Taleb Mohamed
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Immunotherapeutic Targeting of Glioblastoma at the Minimal Residual Disease State.
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive T Cell Therapy; Chemotherapy And Radiotherapy; Chimeric Antigen Receptor T Cells; Glioblastoma; Glioma Stem Cells; Immunotherapy; Immunotherapy Target Discovery; Minimal Residual Disease; Patient Derived Xenografts; Recurrence
Abstract
Glioblastoma (GBM) is the most common and deadliest type of primary brain tumor in adults, with a staggering 90-95% of patients losing their lives to the disease within 5 years of diagnosis. This is because glioblastoma recurs in almost all patient despite an aggressive standard of care (SoC) treatment involving surgery followed by radiotherapy and chemotherapy. There currently exists no standardized treatment protocol upon recurrence. To better understand GBM recurrence, we have previously adapted the clinical SoC treatment to mice engrafted with GBM to model GBM at its lowest point post-treatment. This stage of cancer progression is called the minimal residual disease (MRD). Given that the GBM is practically impossible to treat upon recurrence, MRD presents a valuable yet underutilized window of opportunity for pre-emptive intervention. Upon analyzing cellular expression data extracted from this model, I identified protein tyrosine phosphatase receptor type Z1 (PTPRZ1) as one of the highest expressed genes at MRD. While PTPRZ1 has previously been shown to promote tumor growth in GBM pre-treatment, its role in driving tumor recurrence is yet to be characterized. I hypothesize that interfering with PTPRZ1 activity will decrease the protumor characteristics of recurrent GBM. Furthermore, using engineered T cells to target PTPRZ1 and attack surviving cancer cells post-treatment may significantly prolong remission. GBM recurrence is almost inevitable and ultimately fatal. Treatment at MRD may delay recurrence by targeting GBM when it is vulnerable, thereby significantly improving patient outcomes and quality of life.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Taleb, Mohamed
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~